U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07002034) titled 'RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses' on May 23.
Brief Summary: The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Adjustment Disorder
Intervention: ...